Tvardi Therapeutics (LTS:0HTC) PB Ratio: 2.19 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HTC Tvardi Therapeutics Inc LTS:0HTC
18 GF Score
Price $3.38
! 1 Warning Sign
View Full Analysis

What is Tvardi Therapeutics PB Ratio?

Tvardi Therapeutics LTS:0HTC 18 PB Ratio is 2.19 as of Jul. 17, 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 1,227 Biotechnology companies, Tvardi Therapeutics ranks better than 64.87% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-17), Tvardi Therapeutics's share price is $3.38. Tvardi Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $1.55. Hence, Tvardi Therapeutics's PB Ratio of today is 2.19.

The historical rank and industry rank for Tvardi Therapeutics's PB Ratio or its related term are showing as below:

LTS:0HTC' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.9
Current: 1.9

During the past 4 years, Tvardi Therapeutics's highest PB Ratio was 1.90. The lowest was 0.00. And the median was 0.00.

LTS:0HTC's PB Ratio is ranked better than
64.87% of 1227 companies
in the Biotechnology industry
Industry Median: 2.93 vs LTS:0HTC: 1.90

Back to Basics: PB Ratio

Tvardi Therapeutics  (LTS:0HTC) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Tvardi Therapeutics PB Ratio Related Terms

Tvardi Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics PB Ratio Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
PB Ratio
0.00 0.00 0.00 0.00

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0HTC vs HOWL, TPST, XCUR: PB Ratio Comparison

For the Biotechnology subindustry, Tvardi Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tvardi Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Tvardi Therapeutics's PB Ratio falls into.


LTS:0HTC
18GF Score
Tvardi Therapeutics Inc LTS:0HTC
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tvardi Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Tvardi Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=3.38/1.546
=2.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PB Ratio=Market Cap /(Total Stockholders Equity-Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 2.19 mean?
Tvardi Therapeutics (LTS:0HTC) has a PB Ratio of 2.19 as of Jul. 17, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tvardi Therapeutics and its competitors. According to the industry distribution chart, Tvardi Therapeutics ranks #431 out of 1227 companies in the Biotechnology industry, placing it in the top 35.1%.
Is Tvardi Therapeutics' PB Ratio too high?
Tvardi Therapeutics' current PB Ratio is 2.19. The Biotechnology industry median PB Ratio is 2.93. Tvardi Therapeutics' value of 2.19 is 25.3% below this industry median. Based on the distribution chart, Tvardi Therapeutics ranks #431 out of 1227 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tvardi Therapeutics has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' PB Ratio compare to HOWL and TPST?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #431 out of 1227 companies for PB Ratio. This puts Tvardi Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.93. Tvardi Therapeutics' value of 2.19 is 25.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tvardi Therapeutics's current PB Ratio of 2.19 is 25.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tvardi Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tvardi Therapeutics's current PB Ratio is 2.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current PB Ratio of 2.19. The current PB Ratio is 2.19 and 25.3% below the Biotechnology industry median of 2.93. Tvardi Therapeutics' overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current PB Ratio is 2.19 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
18GF Score

Get the complete analysis for LTS:0HTC

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.38
Price